ClinConnect ClinConnect Logo
Search / Trial NCT06262828

HEARTWISE - P-CARDIAC for Chinese: Population-based Study

Launched by THE UNIVERSITY OF HONG KONG · Feb 13, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

The HEARTWISE - P-CARDIAC trial is studying a new way to predict the risk of heart disease in individuals, particularly among the Chinese population in Hong Kong. This study is focused on developing a tool called P-CARDIAC, which uses advanced technology known as Machine Learning to estimate the risk of having another heart-related event over the next ten years for people who have already experienced a heart issue. The goal is to see how accurate this new risk prediction model is when used in real-life medical settings, especially in clinics that specialize in heart health.

To participate in this study, individuals need to be between 18 and 80 years old and have visited specific medical clinics after experiencing a previous heart-related event, such as a heart attack or stroke. They should also be able to understand English or Traditional Chinese. Participants will have the chance to contribute to improving heart disease care while receiving information that may help their healthcare providers make better decisions for their treatment. It's important to note that people with certain conditions like dementia or severe physical impairments will not be eligible to join the study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Individuals aged 18 - 80 years old who visit the medical or cardiology SOPC clinics at the Queen Mary Hospital (QMH), Pok Oi Hospital (POH), Kwong Wah Hospital (KWH), Princess Margaret Hospital (PMH), Queen Elizabeth Hospital (QEH), Tuen Mun Hospital (TMH) and experienced prior CVD event (such as peripheral artery diseases, coronary heart diseases, myocardial infarction, stroke, revascularization) before the scheduled SOPC clinic visit date are eligible to participate in this study. Participants will be also able to comprehend English or Traditional Chinese as well.
  • Exclusion Criteria:
  • People with history of dementia, psychiatric diseases or physical impairment.

About The University Of Hong Kong

The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.

Locations

Hong Kong, , Hong Kong

Patients applied

0 patients applied

Trial Officials

Sze Ling Celine Chui, PhD

Principal Investigator

School of Nursing, The University of Hong Kong

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported